SELLAS Life Sciences Group, Inc.
NASDAQSELLAS Life Sciences Group enters September with one of the most charged short-selling setups in small-cap biotech — 41% of the free float sold short, essentially no shares left to borrow, and a stock that has surged 32% in a month while slipping 6% this week. The borrow market tells the most extreme story here. Availability has collapsed to just 0.17% of short interest — meaning…
SLS utilization hits 100%, lowest availability in 52 weeks at 0.17%—near-zero shares available to borrow against 40.6% short interest.
SELLAS Life Sciences Group enters September with one of the most charged short-selling setups in small-cap biotech — 41% of the free float sold short, essentially no shares left to borrow, and a stock that has surged…
SELLAS Life Sciences Group reported its Q2 results on August 12 with one of the most heavily contested short positions in small-cap biotech still intact — and the data since the print shows bears have not…
Snapshot as of 11 Sept 2026
SELLAS Life Sciences Group heads into its August 12 earnings report as one of the most heavily shorted small-cap biotechs in the market, with the lending pool telling a story of sustained bear conviction — even as…
SELLAS Life Sciences enters the second week of July in a different borrow regime than it occupied ten days ago — the acute squeeze pressure has partially unwound, but the underlying short conviction has not. The borrow…
SELLAS Life Sciences has crossed into territory where the lending market offers almost nothing to new short sellers. Availability has collapsed to 0.04% — effectively zero. Every share in the lending pool is now out on…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SLS — free to start on ORTEX.
Sign up for free →Open SLS on ORTEX